• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?" [Thromb. Res. 236 (2024) 236-239 TR_8963].

作者信息

Vassart Julie, Didembourg Marie, Morimont Laure, Brisbois Clotilde, Jamart Laurent, Lebreton Aurélien, Mullier François, Donis Nathalie, Favresse Julien, Dogné Jean-Michel, Douxfils Jonathan

机构信息

Clinical Pharmacology and Toxicology Research Unit (URPC), Faculty of Medicine, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Clinical Pharmacology and Toxicology Research Unit (URPC), Faculty of Medicine, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium; QUALIresearch, QUALIblood s.a., Namur, Belgium.

出版信息

Thromb Res. 2024 Aug;240:109066. doi: 10.1016/j.thromres.2024.109066. Epub 2024 Jun 18.

DOI:10.1016/j.thromres.2024.109066
PMID:38897048
Abstract
摘要

相似文献

1
Corrigendum to "Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?" [Thromb. Res. 236 (2024) 236-239 TR_8963].《房颤中的阿孙地昔：药效学数据能否解释其失败原因？》勘误 [《血栓研究》236 (2024) 236 - 239，TR_8963]
Thromb Res. 2024 Aug;240:109066. doi: 10.1016/j.thromres.2024.109066. Epub 2024 Jun 18.
2
Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?阿孙地昔用于心房颤动：药效学数据能否解释其失败原因？
Thromb Res. 2024 Apr;236:236-239. doi: 10.1016/j.thromres.2024.03.001. Epub 2024 Mar 7.
3
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.根据既往口服抗凝药使用情况，比较阿孙地昔或阿哌沙班用于房颤患者：OCEANIC-AF随机临床试验的亚组分析
JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0277.
4
Fibrosis-4 index reflects the severity of tricuspid regurgitation and patient prognosis in atrial fibrillation.纤维化-4指数反映了心房颤动患者三尖瓣反流的严重程度及预后。
Eur J Heart Fail. 2025 Jul 14. doi: 10.1002/ejhf.3761.
5
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.评估新型口服抗凝剂在心房颤动卒中预防试验中疗效和安全性的网状Meta分析的批判性评价
Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Epub 2015 Jan 28.
6
Left atrial pressure and significant tricuspid regurgitation in persistent atrial fibrillation.持续性心房颤动时的左心房压力与显著三尖瓣反流
Front Cardiovasc Med. 2025 Jun 6;12:1575750. doi: 10.3389/fcvm.2025.1575750. eCollection 2025.
7
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.口服因子 XIa 抑制剂 asundexian 与房颤患者的阿哌沙班（PACIFIC-AF）相比的安全性：一项多中心、随机、双盲、双模拟、剂量发现的 2 期研究。
Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3.
8
Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents.在常规和特殊凝血检测中与凝血因子 XIa 抑制剂阿孙地昔和米尔维昔相关的干扰及其通过活性炭基吸附剂的去除
J Thromb Haemost. 2025 Sep;23(9):2819-2829. doi: 10.1016/j.jtha.2025.05.030. Epub 2025 Jun 9.
9
Asundexian versus Apixaban in Patients with Atrial Fibrillation.阿孙地昔与阿哌沙班用于心房颤动患者的比较
N Engl J Med. 2025 Jan 2;392(1):23-32. doi: 10.1056/NEJMoa2407105. Epub 2024 Sep 1.
10
Corrigendum to "D-dimer to fibrinogen ratio predicts early neurological deterioration in ischemic stroke with atrial fibrillation" [Thromb. Res. 229 (2023) 219-224].
Thromb Res. 2024 Jan;233:173. doi: 10.1016/j.thromres.2023.11.001. Epub 2023 Dec 8.